Patent: 10,251,906
✉ Email this page to a colleague
Summary for Patent: 10,251,906
| Title: | Compositions and methods for inducing apoptosis |
| Abstract: | In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
| Inventor(s): | Kopecek; Jindrich Henry (Salt Lake City, UT), Yang; Jiyuan (Salt Lake City, UT), Chu; Te-Wei (Salt Lake City, UT) |
| Assignee: | UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, GA) |
| Application Number: | 14/773,791 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,251,906
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 26-Nov-97 | 10,251,906 | 2034-03-11 |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 26-Oct-09 | 10,251,906 | 2034-03-11 |
| Novartis Pharmaceuticals Corporation | ARZERRA | ofatumumab | Injection | 125326 | 1-Apr-11 | 10,251,906 | 2034-03-11 |
| Novartis Pharmaceuticals Corporation | KESIMPTA | ofatumumab | Injection | 125326 | 20-Aug-20 | 10,251,906 | 2034-03-11 |
| Genentech, Inc. | GAZYVA | obinutuzumab | Injection | 125486 | 1-Nov-13 | 10,251,906 | 2034-03-11 |
| Genentech, Inc. | OCREVUS | ocrelizumab | Injection | 761053 | 28-Mar-17 | 10,251,906 | 2034-03-11 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
